{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:55:25Z","timestamp":1760576125218,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["20142016"],"award-info":[{"award-number":["20142016"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejpb.2021.05.006","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T12:04:16Z","timestamp":1620821056000},"page":"106-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"165","author":[{"given":"Jong Bong","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atheer","family":"Zgair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting Qian","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Voronin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"Soukarieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan Tying","family":"Soh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Gi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwi-yeol","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Gershkovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejpb.2021.05.006_b0005","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/sj.bjc.6604483","article-title":"Tumour-targeted nanomedicines: principles and practice","volume":"99","author":"Lammers","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejpb.2021.05.006_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2013.04.020","article-title":"Oral delivery of anticancer drugs: challenges and opportunities","volume":"170","author":"Thanki","year":"2013","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ejpb.2021.05.006_b0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-012-0212-2","article-title":"A review on various targeted anticancer therapies","volume":"7","author":"Li","year":"2012","journal-title":"Target Oncol."},{"issue":"1","key":"10.1016\/j.ejpb.2021.05.006_b0020","first-page":"56","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.ejpb.2021.05.006_b0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ctrv.2010.04.005","article-title":"Anticancer oral therapy: emerging related issues","volume":"36","author":"Banna","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.ejpb.2021.05.006_b0030","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.bjc.6600591","article-title":"Oral cancer treatment: developments in chemotherapy and beyond","volume":"87","author":"O'Neill","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.ejpb.2021.05.006_b0035","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd2907","article-title":"Cell cycle kinases as therapeutic targets for cancer","volume":"8","author":"Lapenna","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.ejpb.2021.05.006_b0040","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/jm301475f","article-title":"Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities","volume":"56","author":"Shao","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2021.05.006_b0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejmech.2013.08.052","article-title":"Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents","volume":"70","author":"Shao","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejpb.2021.05.006_b0050","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.tips.2008.03.003","article-title":"Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology","volume":"29","author":"Wang","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejpb.2021.05.006_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113244","article-title":"Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents","volume":"214","author":"Shao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejpb.2021.05.006_b0060","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.addr.2007.05.009","article-title":"Estimating drug solubility in the gastrointestinal tract","volume":"59","author":"Dressman","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.ejpb.2021.05.006_b0065","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejpb.2005.03.002","article-title":"Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds","volume":"60","author":"Vertzoni","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.ejpb.2021.05.006_b0070","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/jphp.12361","article-title":"Gastrointestinal characterisation and drug solubility determination in animals","volume":"67","author":"Merchant","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejpb.2021.05.006_b0075","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejpb.2007.10.019","article-title":"Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model","volume":"69","author":"Kagan","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.ejpb.2021.05.006_b0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/path.1700890112","article-title":"Observations on the flora of the alimentary tract of animals and factors affecting its composition","volume":"89","author":"Smith","year":"1965","journal-title":"J. Pathol. Bacteriol."},{"issue":"3","key":"10.1016\/j.ejpb.2021.05.006_b0085","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1258\/002367787781268693","article-title":"Gastrointestinal pH measurement in rats: influence of the microbial flora, diet and fasting","volume":"21","author":"Ward","year":"1987","journal-title":"Lab. Anim."},{"issue":"8","key":"10.1016\/j.ejpb.2021.05.006_b0090","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.29.8.1035","article-title":"Measurement of gastrointestinal pH profiles in normal ambulant human subjects","volume":"29","author":"Evans","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.ejpb.2021.05.006_b0095","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0169-409X(01)00179-X","article-title":"Predicting the impact of physiological and biochemical processes on oral drug bioavailability","volume":"50","author":"Agoram","year":"2001","journal-title":"Adv. Drug Delivery Rev."},{"issue":"4","key":"10.1016\/j.ejpb.2021.05.006_b0100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cpt1978244420","article-title":"Kinetics of acetaminophen absorption and gastric emptying in man","volume":"24","author":"Clements","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.ejpb.2021.05.006_b0105","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0090-9556(24)15233-6","article-title":"A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration","volume":"27","author":"Wang","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.ejpb.2021.05.006_b0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0939-6411(01)00207-7","article-title":"Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility","volume":"53","author":"Takamatsu","year":"2002","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"7","key":"10.1016\/j.ejpb.2021.05.006_b0115","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1248\/bpb.24.790","article-title":"Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles","volume":"24","author":"Ogiso","year":"2001","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.ejpb.2021.05.006_b0120","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00630286","article-title":"Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis","volume":"26","author":"Hammarlund","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejpb.2021.05.006_b0125","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1023\/A:1018993501426","article-title":"Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000","volume":"10","author":"Lennernas","year":"1993","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2021.05.006_b0130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/00003088-200342020-00005","article-title":"A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine","volume":"42","author":"Yin","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.ejpb.2021.05.006_b0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01066319","article-title":"A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption","volume":"15","author":"Plusquellec","year":"1987","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejpb.2021.05.006_b0140","series-title":"Pharmacokinetics: A Modern View","first-page":"173","article-title":"Unusual pharmacokinetics","author":"Wagner","year":"1984"},{"issue":"2","key":"10.1016\/j.ejpb.2021.05.006_b0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cmpb.2010.03.007","article-title":"Modelling the Double Peak Phenomenon in pharmacokinetics","volume":"104","author":"Godfrey","year":"2011","journal-title":"Comput. Methods Programs Biomed."},{"issue":"9","key":"10.1016\/j.ejpb.2021.05.006_b0150","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1023\/A:1015860007380","article-title":"Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine","volume":"9","author":"Williams","year":"1992","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.ejpb.2021.05.006_b0155","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/j.1552-4604.1993.tb03921.x","article-title":"Absorption of danazol after administration to different sites of the gastrointestinal tract and the relationship to single- and double-peak phenomena in the plasma profiles","volume":"33","author":"Charman","year":"1993","journal-title":"J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejpb.2021.05.006_b0160","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/nrd3908","article-title":"Cyclin-dependent kinase inhibitors move into Phase III","volume":"11","author":"Guha","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1-2","key":"10.1016\/j.ejpb.2021.05.006_b0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijpharm.2011.07.011","article-title":"Evaluation of gastrointestinal motility directly from human pharmacokinetic data","volume":"419","author":"Roush","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.ejpb.2021.05.006_b0170","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1002\/jps.23752","article-title":"Modeling of pharmacokinetic systems using stochastic deconvolution","volume":"102","author":"Kakhi","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2021.05.006_b0175","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejps.2012.06.013","article-title":"Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates \u2013 an evaluation and case study using GastroPlus","volume":"47","author":"Heikkinen","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2021.05.006_b0180","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1208\/s12248-012-9372-3","article-title":"The use of modeling tools to drive efficient oral product design","volume":"14","author":"Mathias","year":"2012","journal-title":"AAPS J."},{"issue":"3","key":"10.1016\/j.ejpb.2021.05.006_b0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1742-7843.2005.pto960308.x","article-title":"Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man","volume":"96","author":"Parrott","year":"2005","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"10","key":"10.1016\/j.ejpb.2021.05.006_b0190","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1124\/dmd.107.015644","article-title":"Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs","volume":"35","author":"De Buck","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.ejpb.2021.05.006_b0195","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1023\/A:1016269522828","article-title":"Regional gastrointestinal absorption of ranitidine in the rat","volume":"12","author":"Suttle","year":"1995","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.ejpb.2021.05.006_b0200","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1359-6446(04)03351-3","article-title":"Formulation strategies for absorption windows","volume":"10","author":"Davis","year":"2005","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.ejpb.2021.05.006_b0205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1211\/0022357022511","article-title":"Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine","volume":"56","author":"Kostewicz","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejpb.2021.05.006_b0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5599\/admet.4.1.258","article-title":"Simulated rat intestinal fluid improves oral exposure prediction for poorly soluble compounds over a wide dose range","volume":"4","author":"Berghausen","year":"2016","journal-title":"Admet & Dmpk"},{"issue":"1","key":"10.1016\/j.ejpb.2021.05.006_b0215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1211\/jpp.60.1.0008","article-title":"Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments","volume":"60","author":"McConnell","year":"2008","journal-title":"J. Pharm. Pharmacol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121001302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121001302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:44:27Z","timestamp":1760546667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641121001302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":43,"alternative-id":["S0939641121001302"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.05.006","relation":{},"ISSN":["0939-6411"],"issn-type":[{"type":"print","value":"0939-6411"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}